Calliditas
Calliditas: Additional details and data from competitor (Redeye)

2019-01-17 15:59
Omeros, a competitor to Calliditas, announced today that their Phase III design has been amended following a meeting with the FDA. Further, the company presented additional data from their Phase II study.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Calliditas Therapeutics - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -